Macrolides for the Treatment of Chronic Sinusitis, Asthma, and COPD

Chest

Volumn 125, Issue 2 SUPPL., 2004, Pages 52S-61S

  Gotfried, Mark H ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Pulmonary Associates   (United States)

Author keywords

Anti inflammatory activity; Asthma; Clarithromycin; COPD; Erythromycin; Macrolides; Roxithromycin; Sinusitis

Indexed keywords

ANTIINFLAMMATORY AGENT; CLARITHROMYCIN; ERYTHROMYCIN; IMMUNOMODULATING AGENT; MACROLIDE; ROXITHROMYCIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC SINUSITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOMODULATION; LUNG FUNCTION; MUCOCILIARY CLEARANCE; NOSE SECRETION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 1042299785     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.2_suppl.52S     Document Type: Article

References (69)

1. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429:209-229
2. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31:464-473
3. Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs 2000; 1:169-172
4. Zalewska-Kaszubska J, Gorska D. Anti-inflammatory capabilities of macrolides. Pharmacol Res 2001; 44:451-454
5. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 1996; 20:693-705
6. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 10 1998; 199:1-428
7. Gliklich RE, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg 1995; 113:104-109
8. Winstead W, Barnett SN. Impact of endoscopic sinus surgery on global health perception: an outcomes study. Otolaryngol Head Neck Surg 1998; 119:486-491
9. Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: bench to bedside; current findings, future directions. Otolaryngol Head Neck Surg 1997; 116:S1-S20
10. Ray NF, Baraniuk JN, Thamer M, et al. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol 1999; 103:408-414
11. Georgitis JW, Matthews BL, Stone B. Chronic sinusitis: characterization of cellular influx and inflammatory mediators in sinus lavage fluid. Int Arch Allergy Immunol 1995; 106:416-421
12. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis 1996; 23:1209-23
13. Reilly JS. The sinusitis cycle. Otolaryngol Head Neck Surg 1990; 103:856-861
14. Bachert C, Wagenmann M, Rudack C, et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998; 53:2-13
15. Demoly P, Crampette L, Mondain M, et al. Myeloperoxidase and interleukin-8 levels in chronic sinusitis. Clin Exp Allergy 1997; 27:672-675
16. Rudack C, Stoll W, Bachert C. Cytokines in nasal polyposis, acute and chronic sinusitis. Am J Rhinol 1998; 12:383-388
17. Kikuchi S, Susaki H, Aoki A, et al. Clinical effect of long-term low-dose erythromycin therapy for chronic sinusitis. Pract Otol (Kyoto) 1991; 84:41-47
18. Iino Y, Sugita K, Toriyama M, et al. Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Arch Otolaryngol Head Neck Surg 1993; 119:648-551
19. Cervin A, Kalm O, Sandkull P, et al. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus sursery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg 2002; 126:481-489
20. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol 1996; 525(suppl):73-78
21. Rubin BK, Druce H, Ramirez OE, et al. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155:2018-2023
22. Nishi K, Mizuguchi M, Tachibana H, et al. Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome. Nippon Kyobu Shikkan Gakkai Zasshi 1995; 33:1392-1400
23. Yamada T, Fujieda S, Mori S, et al. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000; 14:143-148
24. MacLeod CM, Hamid QA, Cameron L, et al. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther 2001; 18:75-82
25. Ichimura K, Shimazaki Y, Ishibashi T, et al. Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. Auris Nasus Larynx 1996; 23:48-56
26. Kimura N, Nishioka K, Nishizaki K, et al. Clinical effect of low-dose, long-term roxithromycin chemotherapy in patients with chronic sinusitis. Acta Med Okayama 1997; 51:33-37
27. Suzuki H, Shimomura A, Ikeda K, et al. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med 1997; 182:115-124
28. Suzuki H, Shimomura A, Ikeda K, et al. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope 1997; 107:1661-1666
29. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, US Department of Health and Human Services, 1997; NIH Publication No. 97-4051
30. National Heart, Lung, and Blood Institute. NHLBI morbidity and mortality chartbook 2002. Available at: http://www.nhl-bi.nih.gov/resources/docs/cht-book. htm. Accessed January 12, 2004
31. Kaplan MA, Goldin M. The use of triacetyloleandomycin in chronic infectious asthma. In: Welsh H, Marti-Ibanez F, eds. Antibiotic annual 1958-1959. New York, NY: Interscience Publishers, 1959; 273-276
32. Zieger RS, Schatz M, Sprerling W, et al. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 1980; 66:438-446
33. Wald JA, Friedman BF, Farr RS. An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma. J Allergy Clin Immunol 1986; 78:36-43
34. Ball BD, Hill MR, Brenner M, et al. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy 1990; 65:37-45
35. Flotte TR, Loughlin GM. Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma. Pediatr Pulmonol 1991; 10:178-182
36. Kamada AK, Hill MR, Ikle DN, et al. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993; 91:873-882
37. Eitches RW, Rachelefsky GS, Katz RM, et al. Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children. Am J Dis Child 1985; 139:264-268
38. Siracusa A, Brugnami G, Fiordi T, et al. Troleandomycin in the treatment of difficult asthma. J Allergy Clin Immunol 1993; 92:677-682
39. Miyatake H, Taki F, Taniguchi H, et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991; 99:670-673
40. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 84:594-598
41. Shimizu T, Kato M, Mochizuki H, et al. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994; 106:458-461
42. Gotfried MH, Jung R, Messick C, et al. Placebo controlled trial evaluating the efficacy of clarithromycin in subjects with corticosteroid- dependent asthma [abstract]. J Antimicrob Chemother 1999; 44(suppl):100
43. Garey KW, Rubinstein I, Gotfried MH, et al. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000; 118:1826-1827
44. Shoji T, Yoshida S, Sakamoto H, et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999; 29:950-956
45. Kamoi H, Kurihara N, Fujiwara H, et al. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma 1995; 32:191-197
46. Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 1994; 148:727-732
47. Hahn DL, Bukstein D, Luskin A, et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. Ann Allergy Asthma Immunol 1998; 80:45-49
48. Kraft M, Cassell GH, Henson JE, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 1998; 158: 998-1001
49. Black PN, Scicchitano R, Jenkins CR, et al. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000; 15:254-259
50. Waites KB, Cassell GH, Canupp KC, et al. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother 1988; 32:1500-1502
51. Fenelon LE, Mumtaz G, Hidgwav GL. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 1990; 26:763-767
52. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214-221
53. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36:1573-1574
54. Renaudin H, Bebear C. Comparative. In vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 1990; 9:838-841
55. Kraft M, Cassell GH, Pak J, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002; 121:1782-1788
56. Hahn DL, Golubjatnikov R. Asthma and chlamydial infection: a case series. J Fam Pract 1994; 38:589-595
57. Kraft M, Cassell GH, Bettinger CM, et al. Mycoplasma pneumoniae as a cofactor in chronic asthma [abstract]. Available at:www.abstracts-on-line.com/ abstracts/ATSALL. Accessed January 12, 2004
58. Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001; 164:536-541
59. National Heart, Lung, and Blood Institute. NHLBI data fact sheet: chronic obstructive pulmonary disease (COPD). Available at: http://www.nhlbi. nih.gov/health/public/lung/other/ copd_fact.htm. Accessed January 12, 2004
60. Calverley PM. Modern treatment of chronic obstructive pulmonary disease. Eur Respir J 2001; 34(suppl):60S-66S
61. Van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Ann J Respir Crit Care Med 2002; 166:1358-1363
62. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003; 21:260-266
63. Banerjee D, Hussain S, Khair O, et al. The effects of oral clarithromycin on airway inflammation in moderate to severe chronic obstructive pulmonary disease (COPD): a double blind randomised controlled study [abstract]. Eur Respir J 2001; 18:338S
64. Banerjee D, Clarke B, Hill SL, et al. The effect of 3 months oral clarithromycin on sputum bacterial colonisation in stable moderate to severe chronic obstructive pulmonary disease (COPD) [abstract]. Eur Respir J 2001; 18:1535
65. Banerjee D, Khair O, Honeybourne D. The relationship between pulmonary function, health status, shuttle walk distance with sputum airway inflammation in moderate to severe chronic obstructive pulmonary disease (COPD) [abstract]. Eur Respir J 2001; 18:945
66. Nixon LS, Boorman J, Papagiannis AJ, et al. Circulation and airways inflammatory markers in chronic obstructive pulmonary disease (COPD) during an exacerbation [abstract]. Available at: www.abstracts-on-line.com/abstracts/ ATSALL. Accessed January 12, 2004
67. Nixon LS, Boorman J, Papagiannis AJ, et al. The effect of the length of antibiotic treatment on inflammatory markers in chronic obstructive pulmonary disease [abstract]. Available at: www.abstracts-on-line.com/abstracts/ATSALL. Accessed January 12, 2004
68. Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58:145-149
69. Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med 1995; 34: 469-474